Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in a randomized placebo-controlled study

Désirée Van Der Heijde, Atulya (Atul) Deodhar, Robert D. Inman, Jürgen Braun, Ben Hsu, Michael MacK

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective To compare 3 methods for calculating the Bath Ankylosing Spondylitis Metrology Index (BASMI) score using patients who participated in the GO-RAISE study. Methods Patients with active ankylosing spondylitis (AS) were randomly assigned in a 1:1.8:1.8 ratio to receive subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Lumbar flexion, tragus-to-wall distance, lumbar side flexion, intermalleolar distance, and cervical rotation angle measurements at baseline, week 14, and week 24 were used to calculate the BASMI 2-step (BASMI2), 10-step (BASMI 10), and linear (BASMIlin) scores. Results BASMI 2 scores were generally lower than BASMI10 and BASMI lin scores, which were nearly identical. Median changes from baseline to week 14 in the combined golimumab group were similar to those in the placebo group when using the BASMI2 calculation method (0.00 versus 0.00; P = 0.288). The combined golimumab group showed significantly greater improvement from baseline to week 14 than the placebo group when using the BASMI 10 (-0.20 versus 0.00; P = 0.018) and BASMIlin (-0.31 versus -0.07; P = 0.015) calculation methods, with the latter showing the greatest difference between golimumab and placebo. Guyatt's effect size was better for the BASMIlin and the BASMI10 versus the BASMI2 in the combined golimumab group at week 14 (0.58 and 0.53 versus 0.42, respectively) and week 24 (0.76 and 0.69 versus 0.61, respectively), despite the relatively short period to assess changes in spinal mobility. Conclusion The BASMIlin method was the most sensitive to changes in range of motion exhibited by patients with AS who received golimumab.

Original languageEnglish (US)
Pages (from-to)1919-1922
Number of pages4
JournalArthritis Care and Research
Volume64
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Ankylosing Spondylitis
Baths
Placebos
Subcutaneous Injections
Articular Range of Motion
golimumab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in a randomized placebo-controlled study. / Van Der Heijde, Désirée; Deodhar, Atulya (Atul); Inman, Robert D.; Braun, Jürgen; Hsu, Ben; MacK, Michael.

In: Arthritis Care and Research, Vol. 64, No. 12, 12.2012, p. 1919-1922.

Research output: Contribution to journalArticle

Van Der Heijde, Désirée ; Deodhar, Atulya (Atul) ; Inman, Robert D. ; Braun, Jürgen ; Hsu, Ben ; MacK, Michael. / Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in a randomized placebo-controlled study. In: Arthritis Care and Research. 2012 ; Vol. 64, No. 12. pp. 1919-1922.
@article{e4f0171015bc4109a8354edf731f89f3,
title = "Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in a randomized placebo-controlled study",
abstract = "Objective To compare 3 methods for calculating the Bath Ankylosing Spondylitis Metrology Index (BASMI) score using patients who participated in the GO-RAISE study. Methods Patients with active ankylosing spondylitis (AS) were randomly assigned in a 1:1.8:1.8 ratio to receive subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Lumbar flexion, tragus-to-wall distance, lumbar side flexion, intermalleolar distance, and cervical rotation angle measurements at baseline, week 14, and week 24 were used to calculate the BASMI 2-step (BASMI2), 10-step (BASMI 10), and linear (BASMIlin) scores. Results BASMI 2 scores were generally lower than BASMI10 and BASMI lin scores, which were nearly identical. Median changes from baseline to week 14 in the combined golimumab group were similar to those in the placebo group when using the BASMI2 calculation method (0.00 versus 0.00; P = 0.288). The combined golimumab group showed significantly greater improvement from baseline to week 14 than the placebo group when using the BASMI 10 (-0.20 versus 0.00; P = 0.018) and BASMIlin (-0.31 versus -0.07; P = 0.015) calculation methods, with the latter showing the greatest difference between golimumab and placebo. Guyatt's effect size was better for the BASMIlin and the BASMI10 versus the BASMI2 in the combined golimumab group at week 14 (0.58 and 0.53 versus 0.42, respectively) and week 24 (0.76 and 0.69 versus 0.61, respectively), despite the relatively short period to assess changes in spinal mobility. Conclusion The BASMIlin method was the most sensitive to changes in range of motion exhibited by patients with AS who received golimumab.",
author = "{Van Der Heijde}, D{\'e}sir{\'e}e and Deodhar, {Atulya (Atul)} and Inman, {Robert D.} and J{\"u}rgen Braun and Ben Hsu and Michael MacK",
year = "2012",
month = "12",
doi = "10.1002/acr.21771",
language = "English (US)",
volume = "64",
pages = "1919--1922",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in a randomized placebo-controlled study

AU - Van Der Heijde, Désirée

AU - Deodhar, Atulya (Atul)

AU - Inman, Robert D.

AU - Braun, Jürgen

AU - Hsu, Ben

AU - MacK, Michael

PY - 2012/12

Y1 - 2012/12

N2 - Objective To compare 3 methods for calculating the Bath Ankylosing Spondylitis Metrology Index (BASMI) score using patients who participated in the GO-RAISE study. Methods Patients with active ankylosing spondylitis (AS) were randomly assigned in a 1:1.8:1.8 ratio to receive subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Lumbar flexion, tragus-to-wall distance, lumbar side flexion, intermalleolar distance, and cervical rotation angle measurements at baseline, week 14, and week 24 were used to calculate the BASMI 2-step (BASMI2), 10-step (BASMI 10), and linear (BASMIlin) scores. Results BASMI 2 scores were generally lower than BASMI10 and BASMI lin scores, which were nearly identical. Median changes from baseline to week 14 in the combined golimumab group were similar to those in the placebo group when using the BASMI2 calculation method (0.00 versus 0.00; P = 0.288). The combined golimumab group showed significantly greater improvement from baseline to week 14 than the placebo group when using the BASMI 10 (-0.20 versus 0.00; P = 0.018) and BASMIlin (-0.31 versus -0.07; P = 0.015) calculation methods, with the latter showing the greatest difference between golimumab and placebo. Guyatt's effect size was better for the BASMIlin and the BASMI10 versus the BASMI2 in the combined golimumab group at week 14 (0.58 and 0.53 versus 0.42, respectively) and week 24 (0.76 and 0.69 versus 0.61, respectively), despite the relatively short period to assess changes in spinal mobility. Conclusion The BASMIlin method was the most sensitive to changes in range of motion exhibited by patients with AS who received golimumab.

AB - Objective To compare 3 methods for calculating the Bath Ankylosing Spondylitis Metrology Index (BASMI) score using patients who participated in the GO-RAISE study. Methods Patients with active ankylosing spondylitis (AS) were randomly assigned in a 1:1.8:1.8 ratio to receive subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Lumbar flexion, tragus-to-wall distance, lumbar side flexion, intermalleolar distance, and cervical rotation angle measurements at baseline, week 14, and week 24 were used to calculate the BASMI 2-step (BASMI2), 10-step (BASMI 10), and linear (BASMIlin) scores. Results BASMI 2 scores were generally lower than BASMI10 and BASMI lin scores, which were nearly identical. Median changes from baseline to week 14 in the combined golimumab group were similar to those in the placebo group when using the BASMI2 calculation method (0.00 versus 0.00; P = 0.288). The combined golimumab group showed significantly greater improvement from baseline to week 14 than the placebo group when using the BASMI 10 (-0.20 versus 0.00; P = 0.018) and BASMIlin (-0.31 versus -0.07; P = 0.015) calculation methods, with the latter showing the greatest difference between golimumab and placebo. Guyatt's effect size was better for the BASMIlin and the BASMI10 versus the BASMI2 in the combined golimumab group at week 14 (0.58 and 0.53 versus 0.42, respectively) and week 24 (0.76 and 0.69 versus 0.61, respectively), despite the relatively short period to assess changes in spinal mobility. Conclusion The BASMIlin method was the most sensitive to changes in range of motion exhibited by patients with AS who received golimumab.

UR - http://www.scopus.com/inward/record.url?scp=84870499099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870499099&partnerID=8YFLogxK

U2 - 10.1002/acr.21771

DO - 10.1002/acr.21771

M3 - Article

C2 - 22740380

AN - SCOPUS:84870499099

VL - 64

SP - 1919

EP - 1922

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -